Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Disease
- Biotechnology
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26022
The Parties have agreed to resolve Litigation pursuant to a Settlement Agreement of even date herewith, pursuant to which the Parties have agreed, among other things, that Licensor will agree that regorafenib is not a Collaboration Compound under the Collaboration Agreement, and Licensee will grant Licensor certain rights related to the development and promotion of regorafenib, and pay Licensor royalties based on the sales of regorafenib together with fees for co-promotion services.
Pursuant to this agreement regarding Regorafenib, Licensor grants an exclusive, worldwide license, with the right to grant sublicenses, under the Licensor Developed IP developed pursuant to the Separate Development Program which resulted in the approval for such Separate Indication to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import and have imported, the Product for all indications.
This agreement includes non-exclusive grants back to Licensor.
These agreements also settle and dismiss all claims related to the lawsuit.
Compound means the compound designated as regorafenib, also referred to as BAY 73-4506, together with salts and esters thereof or any other modification which would permit the use of clinical data for regorafenib to be used to establish the efficacy of the modified molecule.
Nexavar, an oral therapy for liver cancer and the treatment of patients with advanced kidney cancer, is currently approved in more than 100 countries worldwide. It is also being evaluated in other cancers by Bayer, Onyx and other parties.
IPSCIO Record ID: 3954
MDV3100 is currently being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.
MDV3100, a new generation of oral anti-androgen, which shows different pharmacological profiles from current anti-androgens, has been shown in preclinical studies to provide more complete suppression of the androgen receptor pathway than bicalutamide, the most commonly used anti-androgen. MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers via three complementary actions – MDV3100 blocks testosterone binding to the androgen receptor, impedes movement of the androgen receptor to the nucleus of prostate cancer cells (nuclear translocation), and inhibits binding to DNA. Preclinical data published in Science earlier this year demonstrated that MDV3100 is superior to bicalutamide in each of these three actions.
IPSCIO Record ID: 30252
IPSCIO Record ID: 26834
The licensee expects to initiate clinical studies of AMD473/NX 473 in one or more cancer indications in the second half of this 2004. Under the agreement, licensee has acquired an exclusive licence, under a portfolio of issued patents and patent applications, to develop, manufacture and commercialise AMD473/NX 473. The patent portfolio relates to composition of matter, formulations and methods of use of AMD473/NX 473 and related analogues and compounds, and includes issued patents and patent applications in all major countries. The agreement also transfers to licensee certain knowledge pertaining to AMD473/NX 473, including clinical and manufacturing data, regulatory submissions and related information. Also under the agreement, licensor will transfer to licensee an inventory of finished AMD473/NX 473 suitable for use in clinical studies. In Phase I studies of AMD473/NX 473 as a single agent and in combination with other cancer therapeutics, antitumour activity was observed in a broad range of cancers. In Phase II monotherapy studies of AMD473/NX 473, objective responses were observed in hormone-resistant prostate cancer, and in second-line ovarian, breast and lung cancers, including platinum-resistant and -sensitive cancers. Existing platinum agents, such as cisplatin and oxaliplatin, exhibit nephrotoxicity and/or neurotoxicity. No clinically significant nephrotoxicity or neurotoxicity has been observed with AMD473/NX 473, to date. Moreover, AMD473/NX 473 has shown oral bioavailability and antitumour activity with oral administration in preclinical studies and has the potential to be the first platinum agent with both intravenous and oral formulations.
